Positive association of adiponectin with soluble thrombomodulin, von Willebrand factor and soluble VCAM-1 in dyslipidemic subjects

Clinical Biochemistry

Volumn 46, Issue 9, 2013, Pages 766-771

  Vaverkova, Helena ^a   Karasek, David ^a   Novotny, Dalibor ^a   Kovarova, Dagmar ^a   Halenka, Milan ^a   Slavik, Ludek ^a   Frohlich, Jiri ^b  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Adhesion molecules; Adiponectin; Plasminogen activator inhibitor 1; Soluble thrombomodulin; Tissue plasminogen activator; Von Willebrand factor

Indexed keywords

ADIPONECTIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FEMALE; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL;

ADIPONECTIN; ADULT; APOLIPOPROTEINS B; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINES; DYSLIPIDEMIAS; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 84877801825     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.02.014     Document Type: Article

References (53)

1. Maeda K., Okubo K., Shimomura I., et al. cDNA cloning and expression of a novel specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
2. Spranger J., Kroke A., Mohlig M., et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361:226-228.
3. Ouchi N., Kihara S., Funahashi T., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671-674.
4. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
5. Kazumi T., Kawaguchi A., Hirano T., et al. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism 2004, 53:589-593.
6. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
7. Frystyk J., Berne C., Berglund L., et al. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007, 92:571-576.
8. Dekker J.M., Funahashi T., Nijpels G., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008, 93:1489-1496.
9. Wannamethee S.G., Whincup P.H., Lennon L., et al. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med 2007, 167:1510-1517.
10. Poehls J., Vassel Ch., Harris T.B., et al. Association of Adiponectin and mortality in older adults: Health ABC study. Diabetologia 2009, 52:591-595.
11. Kizer J.R., BarzilayLH J.I., Kuller L.H., et al. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008, 93:3357-3364.
12. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
13. Tamura T., Furukawa Y., Taniguchi R., et al. Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 2007, 71:623-630.
14. George J., Patal S., Wexler D., et al. Circulating adiponectin levels predict outcome in patients with severe congestive heart failure. Heart 2006, 92:1420-1424.
15. Maiolino G., Cesari M., Sticchi D., et al. Plasma adiponectin for prediction of cardiovascular events and mortality in high-risk patients. J Clin Endocrinol Metab 2008, 93:3333-3340.
16. Cavusoglu E., Ruwende C., Chopra V., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006, 27:2300-2309.
17. Pilz S., Mangge H., Wellnitz B., et al. Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 2006, 91:4277-4286.
18. Menon V., Li L., Wang X., et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:2599-2606.
19. Forsblom C., Thomas M.C., Moran J., et al. Serum adiponectin concentration is a positive predictor of all-cause and cardiovascular mortality in type 1 diabetes. J Intern Med May 26 2011, 10.1111/j.1365-2796.2011.02406.x.
20. Lindsay R.S., Resnick H.E., Zhu J., et al. Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005, 25:15-16.
21. Lawlor D.A., Smith G.D., Ebrahim S., et al. Plasma adiponectin levels are associated with insulin resistance but not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677-5683.
22. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006, 114:623-629.
23. Sattar N., Watt P., Cherry L., et al. High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case control study. J Clin Endocrinol Metab 2008, 93:1846-1849.
24. Wannamethee S.G., Welsh P., Whincup P.H., et al. High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association?. Eur J Cardiovasc Prev Rehabil 2011, 18:65-71.
25. Hattori Y., Nakano Y., Hattori S., et al. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-κB activation in vascular endothelial cells. FEBS Lett 2008, 582:1719-1724.
26. Rothenbacher D., Brenner H., März W., et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005, 26:1640-1646.
27. Wannamethee S.G., Tchernova J., Whincup P., et al. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronary heart disease risk-related parameters. Int J Obes 2007, 31:1089-1098.
28. Wannamethee S.G., Sattar N., Rumley A., et al. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. Diabetes Care 2008, 31:995-1000.
29. Vaverkova H., Karasek D., Novotny D., et al. Positive association of adiponectin with soluble vascular cell adhesion molecule sVCAM-1 levels in patients with vascular disease or dyslipidemia. Atherosclerosis 2008, 197:725-731.
30. Ran J., Xiong X., Liu W., et al. Increased plasma adiponectin closely associates with vascular endothelial dysfunction in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2010, 88:177-183.
31. Fargnoli J.L., Sun Q.I., Olenczuk D., et al. Resistin is associated with biomarkers of inflammation while total and high-molecular weight adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol 2010, 162:281-288.
32. Mertens I., Ballaux D., Funahashi T., et al. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-cholesterol and inflammation. Thromb Haemost 2005, 94:1190-1195.
33. Nagasaki T., Inaba M., Hiura Y., et al. Plasma levels of adiponectin and soluble thrombomodulin in hypothyroid patients with normal thyroid function following levothyroxine replacement therapy. Biomed Pharmacother 2005, 59:571-577.
34. Sniderman A.D. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol 2004, 15:433-438.
35. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement. Circulation 2005, 112:2735-2752.
36. Wu K.K. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol 2003, 14:373-375.
37. Salomaa V., Matei C., Aleksis N., et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999, 353:1729-1734.
38. Olivot J.-M., Labreuche J., Aiach M., et al. Soluble thrombomodulin and brain infarction. Stroke 2004, 35:1946-1951.
39. Blann A.D., Amiral J., McCollum C.N. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischemic heart disease. Eur J Haematol 1997, 59:115-120.
40. Chan S.H., Chen J.H., Li Y.H., et al. Increasing post-event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol 2006, 111:280-285.
41. Blann A.D., McCollum C.N. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999, 10:375-380.
42. Whincup P.H., Danesh J., Walker M., et al. von Willebrand factor and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2002, 23:1764-1770.
43. Spiel A.O., Gilbert J.C., Jilma B. von Willebrand factor in cardiovascular disease. Circulation 2008, 117:1449-1459.
44. Lee K.W., Lip G.Y.H., Tayebjee M., et al. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005, 105:526-532.
45. Karásek D., Vaverková H., Halenka M., et al. Endothelial haemostatic markers in members of families with familial combined hyperlipidemia. Thromb Res 2009, 123:466-475.
46. Maruyoshi H., Kojima S., Funahashi T., et al. Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 2004, 91:1026-1030.
47. Eriksson P., Van Harmelen V., Hoffstedt J., et al. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 2000, 83:545-548.
48. Mertens I., Van der Planken M., Corthouts B., et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001, 33:602-607.
49. Lowe G.D.O., Danesh J., Lewington S., et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 2004, 25:252-259.
50. Kelly C.J., Lyall H., Petrie J.R., et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002, 87:3287-3290.
51. Guray U., Erbay A.R., Guray Y., et al. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol 2004, 96:235-240.
52. Blankenberg S., Rupprecht H.J., Bickel Ch., et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342. for the AtheroGene Investigators.
53. Ridker P.M., Hennekens C.H., Roitman-Johnson B., et al. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.